NVCT Nuvectis Pharma
- 6.350
- -0.050-0.78%
Nuvectis Pharma News
Nuvectis Pharma(NVCT.US) Officer Buys US$3,145 in Common Stock
$Nuvectis Pharma(NVCT.US)$ Officer Poradosu Enrique purchased 500 shares of common stock on May 10, 2024 at an average price of $6.29 for a total value of $3,145.Source: Announcement What is statement
Nuvectis Pharma(NVCT.US) 10% Shareholder Buys US$12,800 in Common Stock
$Nuvectis Pharma(NVCT.US)$ 10% Shareholder BENTSUR RON purchased 2,000 shares of common stock on May 10, 2024 at an average price of $6.4 for a total value of $12,800.Source: Announcement What is stat
Nuvectis Pharma(NVCT.US) Officer Buys US$7,034.16 in Common Stock
$Nuvectis Pharma(NVCT.US)$ Officer Shemesh Shay purchased 1,113 shares of common stock on May 10, 2024 at an average price of $6.32 for a total value of $7,034.16.Source: Announcement What is statemen
Nuvectis Pharma Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Nuvectis Pharma Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : The Nuvectis Pharma (NVCT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $21.00.
HC Wainwright & Co. : The Nuvectis Pharma (NVCT.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $21.00.
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.
Nuvectis Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 219.88% HC Wainwright & Co. → $21 Reiterates Buy → Buy 09/15/2023 219.88% HC Wainwright & Co. →
Strong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug Trials
Nuvectis Pharma Inc Reports Q1 2024 Financial Outcomes
Nuvectis Pharma | 10-Q: Quarterly report
Nuvectis Pharma Q1 EPS $(0.25) Beats $(0.40) Estimate
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.40) by 37.5 percent. This is a 7.41 percent increase over losses of $(0.27
Nuvectis Pharma: Runway Into 2nd Half of 2025 >NVCT
Nuvectis Pharma: Runway Into 2nd Half of 2025 >NVCT
Nuvectis Pharma 1Q Loss $4.17M >NVCT
Nuvectis Pharma 1Q Loss $4.17M >NVCT
Press Release: Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights -- Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARI
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)
Nuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick Facts
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib,
Insider Buys Additional US$51k In Nuvectis Pharma Stock
Nuvectis Pharma(NVCT.US) 10% Shareholder Buys US$51,450 in Common Stocks
$Nuvectis Pharma(NVCT.US)$ 10% Shareholder BENTSUR RON purchased 5,000 shares of Common Stocks on Mar 18, 2024 at an average price of $10.29 for a total value of $51,450.Source: Announcement What is s
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Analysis
Price Target
No Data
